Brisbane, CA, January 11, 2021 – FlemingMartin is pleased to announce that Aimmune Therapeutics, a biopharmaceutical company transforming the lives of people who suffer from serious food allergies, has hired Azfar Qureshi as Head of Finance.
Reporting to President and CEO, Andrew Oxtoby, Azfar brings two decades of progressive financial leadership experience to the position from a diverse career in the biopharmaceutical, alternative energy, and semiconductor industries. Most recently, Azfar served as Head of Financial Planning & Analysis at Dermira (formerly, NASDAQ: DERM), where he played an integral role in successfully launching Qbrexza before integrating the business into Eli Lilly (post-acquisition). Prior to Dermira, Azfar drove Jazz Pharmaceuticals’ (NASDAQ: JAZZ) Commercial FP&A function as revenue grew to more than $1.5 Billion in annual worldwide sales. Earlier in his career, Azfar held key finance roles with Solyndra, Gilead Sciences, and KLA-Tencor. Azfar earned an M.B.A in Corporate Finance from the University of Pittsburgh and received his undergraduate degree in Mechanical Engineering from Florida International University.
Aimmune Therapeutics, a Nestle Health Science Company, is developing and bringing new treatments to people with potentially life-threatening food allergies. PALFORZIA™ is the first and only FDA-approved treatment to help reduce the severity of allergic reactions to peanuts, including anaphylaxis, in children aged 4 through 17. aimmune.com
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com